New: FCF Assistant

We’re testing a new AI assistant to help patients, caregivers, and researchers find information faster. Click the FCF Assistant button in the lower right corner to try it.

Skip to content

About Us
News & Media
- Announcements
- Press Releases
For Researchers

About Fibro
Treatments
Research
Resources & Events
Glossary of terms
Clinical Trials
Join the Fight
Giving

About Fibro
Treatments
Research
Resources & Events
Glossary of terms
Clinical Trials
Join the Fight
Giving

Publications by Hans-Georg Rammensee

Home » Research Authors » Publications by Hans-Georg Rammensee

Publications by Hans-Georg Rammensee

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Get In Touch

20 Horseneck Lane
2nd Floor
Greenwich, CT 06830

(203) 340-7800

info@fibrofoundation.org

Recent Posts

Help fibrolamellar patients access clinical trialsMay 29, 2026
Advancing FLC research – Dr. Sean Ronnekleiv-KellyMay 22, 2026
Paper published by Washington and New York research teamsApril 22, 2026

About FCF

This site does not provide medical advice, diagnosis, or treatment. FCF is a 501 (c) (3) tax exempt public charity.

Contact Us
Terms and Conditions
Privacy Policy
Donor Privacy Policy
Gift Acceptance Policy
AI Use Policy

2026 © Fibrolamellar Cancer Foundation